The effect of exacerbation history on outcomes in the IMPACT trial

IMPACT, a 52-week, randomised, double-blind trial, assessed the efficacy and safety of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus FF/VI or UMEC/VI in patients with symptomatic COPD and a history of exacerbations. Subgroup analyses assessed whether the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Halpin, David M.G., Dransfield, Mark T., Han, MeiLan K., Jones, C. Elaine, Kilbride, Sally, Lange, Peter, Lipson, David A., Lomas, David A., Martinez, Fernando J., Pascoe, Steve, Singh, Dave, Wise, Robert, Criner, Gerard J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286387/
https://www.ncbi.nlm.nih.gov/pubmed/32299860
http://dx.doi.org/10.1183/13993003.01921-2019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286387/
https://www.ncbi.nlm.nih.gov/pubmed/32299860
http://dx.doi.org/10.1183/13993003.01921-2019

Ejemplares similares